1. A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016
- Author
-
Stephanie A. Irving, Holly C. Groom, Padma Dandamudi, Matthew F. Daley, James G. Donahue, Julianne Gee, Rulin Hechter, Lisa A. Jackson, Nicola P. Klein, Elizabeth Liles, Tanya R. Myers, and Shannon Stokley
- Subjects
Vaccine coverage ,Male ,COVID-19 Vaccines ,Adolescent ,VSD, Vaccine Safety Datalink ,Vaccine administration ,Meningococcal Vaccines ,4vHPV, quadrivalent human papillomavirus vaccine ,MenACWY, quadrivalent meningococcal conjugate vaccine ,Human papillomavirus vaccine ,Diphtheria-Tetanus-acellular Pertussis Vaccines ,Article ,Vaccine Safety Datalink ,2vHPV, bivalent human papillomavirus vaccine ,Meningococcal conjugate vaccine ,9vHPV, nine valent human papillomavirus vaccine ,Humans ,Papillomavirus Vaccines ,CDC, Centers for Disease Control and Prevention ,Immunization Schedule ,Retrospective Studies ,Tdap, tetanus, diphtheria and acellular pertussis vaccine ,Vaccines ,General Veterinary ,General Immunology and Microbiology ,SARS-CoV-2 ,Vaccination ,Public Health, Environmental and Occupational Health ,COVID-19 ,ACIP, Advisory Committee on Immunization Practices ,Adolescent vaccination ,Td, tetanus and diphtheria vaccine ,Tetanus, diphtheria, and acellular pertussis vaccine ,United States ,Infectious Diseases ,Molecular Medicine ,Female ,NIS, National Immunization Survey ,EUA, Emergency Use Authorization - Abstract
Background Between May 2005 and March 2007, three vaccines were recommended by the Advisory Committee on Immunization Practices for routine use in adolescents in the United States: quadrivalent meningococcal conjugate vaccine (MenACWY), tetanus, diphtheria and acellular pertussis vaccine (Tdap), and human papillomavirus vaccine (HPV). Understanding historical adolescent vaccination patterns may inform future vaccination coverage efforts for these and emerging adolescent vaccines, including COVID-19 vaccines. Methods This was a descriptive, retrospective cohort study. All vaccines administered to adolescents aged 11 through 18 years in the Vaccine Safety Datalink population between January 1, 2007 and December 31, 2016 were examined. Vaccination coverage was assessed by study year for ≥1 dose Tdap or Td, ≥1 dose Tdap, ≥1 dose MenACWY, ≥1 dose HPV, and ≥3 dose HPV. The proportion of vaccine visits with concurrent vaccination (≥2 vaccines administered at the same visit) was calculated by sex and study year. The most common vaccine combinations administered in the study population were described by sex for two time periods: 2007–2010 and 2011–2016. Results The number of 11–18-year-olds in the study population averaged 522,565 males and 503,112 females per study year. Between January 2007 and December 2016 there were 4,884,553 vaccine visits in this population (45% among males). The overall proportion of concurrent vaccine visits among males was 43% (33–61% by study year). Among females, 39% of all vaccine visits included concurrent vaccination (32–48% by study year). Vaccine coverage for Tdap, MenACWY, and 1- and 3-dose HPV increased across the study period. A wide variety of vaccine combinations were administered among both sexes and in both time periods. Conclusions The high vaccine uptake and multitude of vaccine combinations administered concurrently in the adolescent population of the Vaccine Safety Datalink provide historical patterns with which to compare future adolescent vaccination campaigns.
- Published
- 2021